JP Morgan Healthcare Conference
Top Five Articles on 360Dx Last Week: JP Morgan Healthcare Conference; Quest Update; and More
Last week, readers were most interested in updates provided by Labcorp, Abbott, and others at the JP Morgan Healthcare Conference.
Quanterix Restructuring Efforts on Track, CEO Says at JP Morgan Conference
The restructuring is to scale its operations and assays to better meet both current and anticipated demand for higher-throughput testing, its CEO said.
Rebranded GeneDx Bets Future on Whole-Exome, Whole-Genome Sequencing in Pediatric Rare Disease
Premium
After dropping underdeveloped Sema4 business lines but emphasizing the Centrellis informatics platform, the new GeneDx expects to reach profitability by 2025.
SomaLogic Seeks 'Strategic Alternatives' for Dx Business to Focus on Life Science Market
The proteomics firm is in talks to either spin off its SomaSignal assays unit or to partner with another company to boost its diagnostics efforts.
JP Morgan Healthcare Conference, Day 3: Invitae, Bio-Rad, Bio-Techne, Opko
On the penultimate day of the conference, Invitae provided color on its recent decisions to pull out of certain businesses, while Bio-Rad talked about its clinical plans.